Market Place
Sourcing Support
All News #Library
Biotech
FDA Accepts Zipalertinib NDA for EGFR Exon 20 NSCLC Cancer
28 Apr 2026 //
PHARMIWEB
Taiho Oncology Names Peter Melnyk President & CEO
28 Jan 2026 //
BUSINESSWIRE
Taiho Oncology Presents Azacitidine, Decitabine Data at ASH 2025
08 Dec 2025 //
PR NEWSWIRE
Taiho Oncology Europe Launches Lytgobi For Cholangiocarcinoma
03 Dec 2025 //
PHARMIWEB
Taiho, Cullinan Start NDA Submission For Zipalertinib In NSCLC
20 Nov 2025 //
PR NEWSWIRE
Taiho Oncology, Cullinan Therapeutics Present Zipalertinib Data
13 Oct 2025 //
PR NEWSWIRE
Cullinan, Taiho`s NSCLC Shows `Strong Activity`, Paves Way to FDA
10 Sep 2025 //
BIOSPACE
Taiho & Cullinan Present Zipalertinib Data at IASLC Conference
09 Sep 2025 //
PR NEWSWIRE
Taiho Oncology, Cullinan Therapeutics` Zipalertinib abstracts
22 Jul 2025 //
PR NEWSWIRE
Taiho’s Inqovi Combo sNDA Accepted By US FDA For AML
09 Jul 2025 //
PR NEWSWIRE
Taiho & Cullinan Announce Phase 1/2 Data Published
01 Jun 2025 //
PR NEWSWIRE
Cullinan, Taiho, and Taiho Oncology to Present Zipalertinib Trial
22 May 2025 //
GLOBENEWSWIRE
FDA approves Taiho`s Lonsurf with bevacizumab for metastatic colorectal cancer
03 Aug 2023 //
ENDPTS
FDA Approves LONSURF in Combination With Bevacizumab for mCRC
02 Aug 2023 //
PR NEWSWIRE
EC Grants Conditional Marketing Authorization for Taiho`s Lytgobi Tablets
05 Jul 2023 //
PR NEWSWIRE
Taiho Oncology & Servier Announce in New Engl& Journal pH 3 Data for (LONSURF®)
03 May 2023 //
BUSINESSWIRE
U.S. FDA Accepts for Priority Review Taiho Onc`s sNDA for Trifluridine/Tipiracil
18 Apr 2023 //
PR NEWSWIRE
Taiho to Publish in The New England Journal of Medicine for Futibatinib
18 Jan 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.